CAP-CD56+CD271+ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis
Quick Facts
- Publication title: CAP-CD56+CD271+ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis
- Journal: Bioact Mater
- Year: 2025
- DOI: 10.1016/j.bioactmat.2025.10.027
- PMID/PMCID: 41282412; PMC12639267
Research overview
This study aimed to develop a novel, targeted therapy for lumbar facet joint osteoarthritis (LFJ OA) by identifying a potent bone mesenchymal stem cell (BMSC) subpopulation for cartilage regeneration, engineering its exosomes (Exos) for specific delivery, and incorporating them into a sustained-release hydrogel system. A CD56+CD271+ BMSCs subpopulation with potent cartilage regeneration potential within the human bone marrow was identified through single-cell RNA sequencing and then isolated.
Key findings
Compared with conventional BMSCs, the CD56+CD271+ BMSCs subpopulation and its derived exosomes demonstrated significantly enhanced pro-chondrogenic and anti-senescence capabilities compared to conventional BMSCs.
CAP modification substantially improved in vivo targeting efficiency to chondrocytes, whereas the PVA/SA hydrogel enabled sustained exosome release, prolonging retention at injury sites.
Implantation of the integrated CAP-Exos-PVA/SA system markedly improved osteoarthritis cartilage structure, increased matrix deposition, and suppressed the expression of matrix metalloproteinase-13 (MMP-13) and senescence markers (p16/p21/p53).
Mechanistic studies revealed that the Exo-mediated delivery of miR-210-3p inhibited hypoxia-inducible factor-3α (HIF-3α) expression in chondrocytes.
Study design
A CD56+CD271+ BMSCs subpopulation with potent cartilage regeneration potential within the human bone marrow was identified through single-cell RNA sequencing and then isolated.
Exos were subsequently extracted from this specific subpopulation and engineered with a chondrocyte-specific antigen peptide (CAP) to generate CAP-CD56+CD271+ BMSCs Exos.
A polyvinyl alcohol (PVA)/sodium alginate (SA) composite hydrogel was developed to serve as a sustained-release carrier for these targeted exosomes.
Echo Biotech Role
Echo Biotech contributed targeting-peptide/surface modification; the study also used or cited ExoBrooch™.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Targeting Peptide / Surface Modification, Research Reagent / Product Supply
Related products or reagents: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
References
Original publication: CAP-CD56+CD271+ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis Bioactive Materials. 2025. DOI: 10.1016/j.bioactmat.2025.10.027. PMID/PMCID: 41282412; PMC12639267.